502609-47-4

Basic information

• Product Name: 4-HydroxyMethyl-4-Methyltetrahydro-2H-pyran
• Synonyms: 4-HydroxyMethyl-4-Methyltetrahydro-2H-pyran;4-(HydroxyMethyl)-4-Methyltetrahydropyran;(4-Methyl-tetrahydro-pyran-4-yl)-methanol;(4-methyltetrahydro-2H-pyran-4-yl)methanol
• CAS NO: 502609-47-4
• Molecular Formula: C7H14O2
• Molecular Weight: 130.18486
• Mol File: 502609-47-4.mol

Chemical Properties

• Boiling Point: 211.7±8.0 °C(Predicted)
• Appearance: /
• Density: 0.967±0.06 g/cm3(Predicted)
• PKA: 14.85±0.10(Predicted)
• CAS DataBase Reference: 4-HydroxyMethyl-4-Methyltetrahydro-2H-pyran(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HydroxyMethyl-4-Methyltetrahydro-2H-pyran(502609-47-4)
• EPA Substance Registry System: 4-HydroxyMethyl-4-Methyltetrahydro-2H-pyran(502609-47-4)

Safety Data

• Hazardous Substances Data: 502609-47-4(Hazardous Substances Data)

Usage

Uses

Used in Flavor and Fragrance Industry:
4-HydroxyMethyl-4-Methyltetrahydro-2H-pyran is used as a flavor and fragrance additive for its ability to impart a mildly sweet scent and taste to food and beverages. Its use in this industry is attributed to its capacity to enhance the sensory experience of consumer products without posing health risks when used within safe concentrations.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 4-HydroxyMethyl-4-Methyltetrahydro-2H-pyran serves as a building block in the synthesis of various drugs and organic compounds. Its role in drug development is crucial, as it contributes to the creation of new medicinal agents that address a range of health conditions.
Used in Chemical Synthesis:
Beyond its applications in the flavor, fragrance, and pharmaceutical sectors, 4-HydroxyMethyl-4-Methyltetrahydro-2H-pyran is also utilized in the broader field of chemical synthesis. Its versatility as a chemical intermediate allows for its incorporation into a wide array of organic compounds, expanding its utility across different chemical applications.

Upstream product

• 861161-92-4 ethyl 4-methyltetrahydro-2H-pyran-4-carboxylate 
• 96835-17-5 ethyl tetrahydro-2H-pyran-4-carboxylate 
• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 443912-70-7 methyl 4-methyltetrahydro-2H-pyran-4-carboxylate 

Downstream Products

• 65626-22-4 4-methyltetrahydro-2H-pyran-4-carbaldehyde 

Relevant articles and documents

3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

Provided are cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor, compositions comprising said compounds, and uses of said compounds in the treatment or prevention of diseases in which M4 muscarinic acetylcholine receptors are involved, especially neurological and psychiatric disorders and diseases.

3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.

Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment o

Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia

Thermosensitive transient receptor potential melastatin 8 (TRPM8) antagonists are considered to be potential therapeutic agents for the treatment of cold hypersensitivity. The discovery of a new class of TRPM8 antagonists that shows in vivo efficacy in the rat chronic constriction injury (CCI)-induced model of neuropathic pain is described.

2-Aminopyrimidine modulators of the histamine H4 receptor

2-Aminopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 /su

NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5

Compounds of formula (I) wherein neither R4 nor R5 is hydrogen; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).